This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse | MicrobiomeTrials
← Back to trials NCT07437963
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-28Est. Completion: 2029-09-30
Enrollment target: 76 participantsOther microbiome trials you might be interested in Neuroblastoma Ganglioneuroblastoma
Patients with recurrent or refractory neuroblastoma are resistance to conventional chemotherapy. For this reason, the in…
Seattle, United States Est. completion Nov 2023
Relapsed Neuroblastoma Refractory Neuroblastoma High-Risk Neuroblastoma Ganglioneuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and youn…
Shenzhen, China Est. completion Mar 14, 2027